Benzinga | Dec 14, 2021 08:33AM EST

EF Hutton Initiates Coverage On Pasithea Therapeutics with Buy Rating, Announces Price Target of $3.25

EF Hutton analyst Constantine Davides initiates coverage on Pasithea Therapeutics (NASDAQ:KTTA) with a Buy rating and announces Price Target of $3.25.